One of the reasons biotech stocks can be your portfolio’s biggest winners is because of the massive profits companies see after releasing a blockbuster drug – especially with the exorbitantly high prices of this year’s new treatments.
- These Biotech Stocks Are Tied to the World’s Most Expensive New Drugs
- This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough
- Merck (MRK) Shares Rise, Pfizer (PFE) Stock Slumps on Mixed Earnings
Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.
But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.
Two American pharmaceutical giants reported earnings this morning, both showing flagging sales - but one ended the day with a gain.